Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study has been withdrawn prior to enrollment.
(Study canceled based on results of different study with similar hypothesis, investigational agent, & patient)
Information provided by (Responsible Party):
Centocor, Inc. Identifier:
First received: December 23, 2010
Last updated: January 25, 2013
Last verified: January 2013
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is added to VELCADE and dexamethasone in subjects with relapsed or refractory multiple myeloma.

Condition Intervention Phase
Multiple Myeloma
Drug: Placebo, Velcade and dexamethasone
Biological: Siltuximab, Velcade and dexamethasone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Centocor, Inc.:

Primary Outcome Measures:
  • Progression-free survival (PFS) [ Time Frame: Event driven, i.e. every 3-4 weeks until progression, death, or end of study (5 years after first patient is dosed) ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: Every 3 months until death or end of study (5 years after 1st patient is dosed) ]
  • Overall response rate [ Time Frame: Every 3 weeks until disease progression or end of study (5 years after 1st patient is dosed) ]
  • Siltuximab pharmacokinetic evaluations (Cmin, Cmax) to provide information on the pharmacokinetic profile of siltuximab [ Time Frame: Day 1 of Cycles 1, 2, 3, 5, 7, 11, 15, and 19 and during the follow-up period (12 weeks after last dose) ]
  • Dexamethasone pharmacokinetic evaluations (Cmin, AUC[t1-t2]) from approx. 30 patients from each treatment arm to provide information on the pharmacokinetic profile of dexamethasone [ Time Frame: Pre-dose on Day 1 of Cycles 1, 2 and 3; at Cycle 3 measured 1, 2, 4, 6 and 24 hours after dose ]
  • Number of adverse events as a measure of safety and tolerability [ Time Frame: Routinely until 30 days after last dose at a minimum, or until end of study ]

Enrollment: 0
Study Start Date: July 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 001
Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
Biological: Siltuximab, Velcade and dexamethasone
Given in 21-day treatment cycles
Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
Drug: Placebo, Velcade and dexamethasone
Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle

Detailed Description:
This is a research study with an experimental drug called siltuximab (also known as CNTO 328). Siltuximab is being developed to see if it may be useful in treating multiple myeloma, including multiple myeloma that has returned after (relapsed) or did not respond (refractory) to previous treatment. Multiple myeloma is a type of cancer that affects the blood and bone marrow. The cancer cells in the bone marrow can cause the normal bone marrow cells to breakdown. This can result in low levels of red blood cells (which may make the patient feel tired or fatigued), low levels of white blood cells (which may increase the patient's chances of infections) or low levels of platelets (which may increase risk of bleeding). The cancer cells can cause damage to the normal bone. This can cause bone pain, bone fractures, and can increase the level of calcium in the blood. The cancer cells also make proteins (called M-proteins), which can result in damage to other organs, especially the kidneys. Siltuximab is a chimeric (part mouse and part human) antibody (immunoglobulin that is important for fighting infection). Siltuximab blocks another small protein called Interleukin 6 (IL-6). The body makes IL-6 naturally, and at normal levels it is important for the inflammatory response. But high levels of IL-6 can help cancer cells grow and interfere with chemotherapy drugs killing cancer cells. Cancer-related sicknesses such as weight loss, bone weakening, and depression have been linked to high levels of IL-6. This study tests the effectiveness and safety of siltuximab when it is taken together with Velcade and dexamethasone. There are two treatment groups, Arm A and Arm B. To try to make sure the groups are similar, patients will be put into Arm A or Arm B, randomly (by chance), like flipping a coin. Patients in Arm A will receive siltuximab plus Velcade and dexamethasone. Patients in Arm B will receive placebo plus Velcade and dexamethasone. About 500 patients will participate in the study. Velcade, also known as bortezomib, is injected directly into the vein all at once. This is called an intravenous (IV) push. Siltuximab or placebo is given as a 1 hour IV infusion through a small tube that goes directly into the vein. Dexamethasone is given orally. The treatment period is divided into cycles lasting about 21 days which will last until the patient's multiple myeloma gets worse, side effects that are not acceptable happen or when the patient decides to withdraw consent for treatment, whichever occurs first. Siltuximab 11mg/kg or placebo will be given on Day 1 of every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles 1-8, and on Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the day of and the day after each Velcade dose. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g. blood pressure), and checking the occurrence and severity of adverse events. Disease assessments will also be performed and include obtaining and evaluating blood and 24 hour urine samples, bone marrow aspirate and/or biopsy samples and clinical and radiologic evaluations. After treatment, patients will enter the follow-up period, which includes visits up to 12 weeks after the last dose and checks every three months until death or the end of the study. Patients who stop treatment before their multiple myeloma gets worse will have disease assessments until their disease gets worse, they start a new multiple myeloma treatment, they decide to withdraw consent for study participation or the end of the study, whichever happens first. Siltuximab or placebo plus Velcade and dexamethasone will be given in 21-day treatment cycles until worsening of disease (progression), unacceptable toxicity or withdrawal of consent for treatment, whichever comes first. Siltuximab 11 mg/kg or placebo will be given on Day 1 of every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles 1-8, and on Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the day of and the day after each Velcade dose.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma requiring treatment
  • Measurable secretory disease, defined as either serum M-protein >=1 g/dL or urine M-protein (light chain) >=¿200 mg/24 hours
  • Must have received 1 to 3 lines of prior treatment for multiple myeloma
  • Must have achieved a response (Minimal Response or better) to at least 1 prior line of treatment
  • Must have progressed on or been refractory (defined as < Minimal Response or disease progression within 60 days of last dose) to the most recent line of treatment
  • Must not be refractory to any previous line of treatment that included a proteasome inhibitor
  • Qualifying hematology and chemistry laboratory results.

Exclusion Criteria:

  • Diagnosis of primary amyloidosis, plasma cell leukemia, or other conditions in which a paraprotein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy
  • Allogeneic bone marrow transplantation within 28 days
  • Bone marrow transplant planned within 12 months after study start
  • Chemotherapy or radiation therapy within 21 days
  • Clinically significant infection, including known HIV or hepatitis C infection, or known hepatitis B surface antigen positivity
  • Major surgery within 21 days before or planned during the study
  • Subjects who the investigator believes would not tolerate starting doses of VELCADE or dexamethasone
  • Significant cardiac disease or myocardial infarction within 6 months
  • Vaccination with live attenuated vaccines within 4 weeks
  • Prior exposure to agents targeting IL-6 or the IL-6 receptor
  • Received any investigational agent within 30 days¿
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01266811

  Hide Study Locations
United States, Iowa
Iowa City, Iowa, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Ohio
Toledo, Ohio, United States
United States, Pennsylvania
Willow Grove, Pennsylvania, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Adelaide, Australia
Camperdown, Australia
Heidelberg, Australia
Parkville, Australia
Prahran, Australia
Edegem, Belgium
Liège, Belgium
Turnhout, Belgium
Yvoir, Belgium
Plovdiv N/A, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Toronto, Canada
Czech Republic
Hradec Kralove, Czech Republic
Liberec, Czech Republic
Praha 2, Czech Republic
Praha, Czech Republic
Gandhinagar Guiarat, India
Korea, Republic of
Hwasun Gun, Korea, Republic of
Seoul, Korea, Republic of
Apeldoorn, Netherlands
Deventer, Netherlands
Zwolle, Netherlands
New Zealand
Christchurch, New Zealand
Grafton, New Zealand
Nz 9 Takapuna Auckland, New Zealand
Palmerston North, New Zealand
Brzozow, Poland
Gdansk, Poland
Lodz, Poland
Opole, Poland
Wroclaw, Poland
Ankara, Turkey
Bursa, Turkey
Edirne, Turkey
Cherkassy, Ukraine
Dnepropetrovsk, Ukraine
Kharkov, Ukraine
Khmelnitskiy, Ukraine
Kiev, Ukraine
Odessa, Ukraine
Simferopol, Ukraine
Vinnitsa, Ukraine
United Kingdom
Nottingham, United Kingdom
Sponsors and Collaborators
Centocor, Inc.
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
  More Information

Responsible Party: Centocor, Inc. Identifier: NCT01266811     History of Changes
Other Study ID Numbers: CR017743
CNTO328MMY3001 ( Other Identifier: Centocor, Inc. )
Study First Received: December 23, 2010
Last Updated: January 25, 2013

Keywords provided by Centocor, Inc.:
CNTO 328
Monoclonal Antibody
Multiple Myeloma
Relapsed or Refractory

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on May 25, 2017